GLP‑1s: eat for muscle
Nutritionists and recent reporting stress that people taking GLP‑1 drugs often need to deliberately prioritize protein, fiber and key nutrients because the drugs can suppress appetite and risk unintentional under‑eating. (businessinsider.com) Coverage also highlights that semaglutide and tirzepatide produced the largest weight losses across 22 trials, while some drugs like liraglutide remain more cost‑effective as patents change—plus there’s early evidence GLP‑1s can improve liver and heart markers even when weight loss is limited. (ajmc.com) (wisn.com)
Glucagon-like peptide 1 drugs cut appetite so sharply that many patients have to plan meals around protein, fiber, and other nutrients instead of hunger cues. (nih.gov) These medicines mimic gut hormones that slow stomach emptying and reduce hunger, which helps people eat less but can also leave them short on calories, vitamins, and protein if they do not eat deliberately. Four medical groups said in a 2025 joint advisory that clinicians should screen for diet quality, muscle strength, and body composition when starting treatment. (nih.gov) Rob Hobson, a United Kingdom nutritionist interviewed by Business Insider in April 2026, said each meal on a glucagon-like peptide 1 drug should pair a high-quality protein with fruit or vegetables, a healthy fat, and a whole food such as beans, rice, bread, or potatoes. He said chicken, fish, eggs, and tofu are practical anchors when appetite is low. (businessinsider.com) The nutrition focus comes as the drugs keep posting the biggest weight-loss numbers in the category. A 22-trial review covering more than 40,000 adults found semaglutide 2.4 milligrams and tirzepatide produced the strongest results, while liraglutide remained a cheaper option as its patent expiry changes pricing. (ajmc.com) That same review said gastrointestinal side effects were common, but pancreatitis and serious adverse events were similar to placebo across the randomized trials it analyzed. In the SURPASS-1 trial, tirzepatide 15 milligrams cut body weight by 9.5 kilograms at 40 weeks, and 72% of participants lost at least 5% of baseline weight. (ajmc.com) Doctors are paying closer attention to muscle because weight loss does not come only from fat. The 2025 joint advisory warned that calorie reduction on these drugs can bring muscle and bone loss, and it said protein alone is not enough without strength training. (nih.gov) Researchers are also finding benefits beyond the scale. In the SELECT trial, semaglutide 2.4 milligrams reduced major cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who did not have diabetes. (nejm.org) In the STEP-HFpEF trial, 529 patients with obesity-related heart failure with preserved ejection fraction were assigned to semaglutide or placebo for 52 weeks, and semaglutide improved symptoms and physical limitations. That means some patients may see heart-related gains even before weight loss tells the full story. (nejm.org) Liver data are moving in the same direction. A phase 3 trial reported in April 2025 found semaglutide improved metabolic dysfunction-associated steatohepatitis in nearly two-thirds of patients at 72 weeks, a result that adds to newer reports that some liver effects may be partly independent of weight loss. (jamanetwork.com) The practical message for patients is narrower than the hype around the drugs: smaller portions have to work harder. On glucagon-like peptide 1 treatment, eating less is often the easy part, and eating enough of the right things is the part that takes planning. (nih.gov)
